Drug intelligence / Profile preview

EB101

Development stage: Preclinical
Lead developer: Abeona Therapeutics
Modality: Vaccines & Immunotherapeutics
Administration: Topical

Overview

EB101 is an anti-amyloid-β vaccine under investigation for the treatment of Alzheimer's disease. It has been studied in APP/PS1 double-transgenic mouse models, which are utilized to characterize immunocytochemical patterns of Alzheimer's disease-like pathology as a model for human AD.

Targets

Aβ (Amyloid-beta peptides and aggregates)

Beyond the preview

Go deeper on EB101.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on EB101.